Apolipoprotein A-I: A Molecule of Diverse Function

Mangaraj, Manaswini; Nanda, Rachita; Panda, Suchismita

doi:10.1007/s12291-015-0513-1

Cited by 104 publications

(79 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, this biomarker is a convenient and reproducible laboratory parameter. In addition to simply serving as a shuttle of cholesterol cargo during RCT, an expanded range of physiological functions of apoA1 have been described, including anti-inflammatory, anti-apoptotic, anti-parasitic, anti-bacterial, anti-viral, and anti-oxidant activities [40]. Chronic inflammation, infection, oxidative stress, and lipids have been related to tumorigenesis [41-43].…”

Section: Discussionmentioning

confidence: 99%

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

Zhou

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Serum apolipoprotein A1 (apoA1) has been reported to be abnormally expressed in several malignancies. However, the prognostic role of apoA1 in solid tumors is still controversial. We conducted this meta-analysis to obtain a more accurate evaluation of prognostic significance of apoA1 in Chinese patients with solid tumors. Methods: A comprehensive literature search of electronic databases was carried out up to August 2018. We included studies investigating the association between pretreatment serum apoA1 level and clinicopathological features, including survival outcomes, in solid tumors. Hazard ratios (HRs) and odds ratio (ORs) with 95% confidence intervals (CIs) were applied as effect size estimates. Results: A total of 13 studies and 8052 patients were included in our meta-analysis. Elevated level of pretreatment serum apoA1 was markedly associated with an improved OS (pooled HR = 0.608, 95% CI = 0.557 – 0.665, P < 0.001). The statistical significances were observed in all cancer types, including digestive system malignancies (pooled HR = 0.633; 95% CI = 0.550–0.727; P < 0.001), urinary system cancers (pooled HR = 0.471; 95% CI = 0.352–0.630; P < 0.001), nasopharyngeal cancer (pooled HR = 0.642; 95% CI = 0.538–0.766; P < 0.001) and non-small cell lung cancer (pooled HR = 0.526; 95% CI = 0.329–0.841; P = 0.007), but not in breast cancer (pooled HR = 0.573; 95% CI = 0.266–1.246; P = 0.155). Meanwhile, cancer patients with a low level of serum apoA1 suffered an unfavorable DFS (pooled HR = 0.714, 95% CI = 0.603 – 0.845, P < 0.001). Moreover, abnormal serum apoA1 was significantly correlated to tumor size (pooled OR = 0.640, 95% CI = 0.475 – 0.863, P = 0.003), tumor differentiation (pooled HR = 0.724, 95% CI = 0.565 – 0.929, P = 0.011), and tumor stage (pooled HR = 0.493, 95% CI = 0.384 – 0.633, P < 0.001). Conclusion: Elevated level of pretreatment serum apoA1 was significantly associated with longer survival in patients with solid tumors. Pretreatment serum apoA1 could serve as a novel positive factor for malignant patient prognosis in Chinese population.

show abstract

Section: Discussionmentioning

confidence: 99%

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

Zhou

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…In addition to its role in cholesterol transport, other vascular beneficial effects have been attributed to apoA-I (Mangaraj et al, 2016). Recent studies have reported a potential anti-inflammatory role for apoA-I in the regulation of monocyte/macrophage recruitment to local sites of inflammation, via modulation of lipid rafts in cellular membranes which resulted in suppression of PI3K/Akt signaling (Iqbal et al, 2016).…”

Section: Apolipoprotein Mimetic Peptidesmentioning

confidence: 99%

The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease

et al. 2017

View full text Add to dashboard Cite

Cardiovascular disease (CVD) remains a leading cause of mortality and morbidity worldwide. Numerous therapies are currently under investigation to improve pathological cardiovascular complications, but yet, there have been very few new medications approved for intervention/treatment. Therefore, new approaches to treat CVD are urgently required. Attempts to prevent vascular complications usually involve amelioration of contributing risk factors and underlying processes such as inflammation, obesity, hyperglycaemia, or hypercholesterolemia. Historically, the development of peptides as therapeutic agents has been avoided by the Pharmaceutical industry due to their low stability, size, rate of degradation, and poor delivery. However, more recently, resurgence has taken place in developing peptides and their mimetics for therapeutic intervention. As a result, increased attention has been placed upon using peptides that mimic the function of mediators involved in pathologic processes during vascular damage. This review will provide an overview on novel targets and experimental therapeutic approaches based on peptidomimetics for modulation in CVD. We aim to specifically examine apolipoprotein A-I (apoA-I) and apoE mimetic peptides and their role in cholesterol transport during atherosclerosis, suppressors of cytokine signaling (SOCS)1-derived peptides and annexin-A1 as potent inhibitors of inflammation, incretin mimetics and their function in glucose-insulin tolerance, among others. With improvements in technology and synthesis platforms the future looks promising for the development of novel peptides and mimetics for therapeutic use. However, within the area of CVD much more work is required to identify and improve our understanding of peptide structure, interaction, and function in order to select the best targets to take forward for treatment.

show abstract

“…AGPAT1 and AGPAT2 play roles in converting lysophosphatidic acid (LPA) into phosphatidic acid (PA) (Takeuchi and Reue 2009). APOA1, APOA4, and APOB encode key apolipoproteins to carry fats and fat-like substances in the blood (Mangaraj et al 2016;Qu et al 2019). Remarkably, we found the positive selection of one gene, ABCG5, which encodes sterolin-1 and works together with sterolin-2, encoded by gene ABCG8, to form a protein called sterolin.…”

Section: Resultsmentioning

confidence: 84%

“…MTTP is involved in the transport of triglycerides, cholesteryl esters, and phospholipids (Hussain et al 2012). APOA4 and APOB encode two key apolipoproteins responsive to carrying fats and fat-like substances in the blood (Mangaraj et al 2016;Qu et al 2019). Unlike PDA and FDA, CDA showed the lowest number of PSGs, and only three PSGs (SI, HKDC1, and ATP1B4) were detected.…”

Section: Resultsmentioning

confidence: 99%

Trophic shift and the origin of birds

2020

Preprint

View full text Add to dashboard Cite

Birds are characterized by evolutionary specializations of both locomotion (e.g., flapping flight) and digestive system (toothless, crop, and gizzard), while the potential selection pressures responsible for these evolutionary specializations remain unclear. Here we used a recently developed molecular phyloecological method to reconstruct the diets of the ancestral archosaur and of the common ancestor of living birds (CALB). Our results showed that the ancestral archosaur exhibited a predominant Darwinian selection of protein and fat digestion and absorption, whereas the CALB showed a marked enhanced selection of carbohydrate and fat digestion and absorption, suggesting a trophic shift from carnivory to herbivory (fruit, seed, and/or nut-eater) at the archosaur-to-bird transition. The evolutionary shift of the CALB to herbivory may have essentially made them become a low-level consumer and, consequently, subject to relatively high predation risk from potential predators such as gliding maniraptorans, from which birds descended. Under the relatively high predation pressure, ancestral birds with gliding capability may have then evolved not only flapping flight as a possible anti-predator strategy against gliding predatory maniraptorans but also the specialized digestive system as an evolutionary tradeoff of maximizing foraging efficiency and minimizing predation risk. Our results suggest that the powered flight and specialized digestive system of birds may have evolved as a result of their tropic shift-associated predation pressure.

show abstract

Apolipoprotein A-I: A Molecule of Diverse Function

Abstract: Apolipoprotein A-I (apo A-I) an indispensable component and a major structural protein of high-density lipoprotein (HDL), plays a vital role in reverse cholesterol transport and cellular cholesterol homeostasis since its identification.

Cited by 104 publications

References 50 publications

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease

Trophic shift and the origin of birds

Contact Info

Product

Resources

About